An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia

Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in developing cou...

Full description

Saved in:
Bibliographic Details
Published in:Biomédica
Main Authors: Jefferson Antonio Buendía, Carlos Vallejos, Andrés Pichón-Rivière
Format: Artigo
Language:Inglês
Published: Instituto Nacional de Salud 2013
Subjects:
Medicina
Positive
Colombia
Breast cancer
Human Epidermal Growth Factor Receptor 2
Online Access:https://www.redalyc.org/articulo.oa?id=84329151010
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items